[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Erasca Inc (ERAS)

Erasca Inc (ERAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,951,820
  • Shares Outstanding, K 310,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,550 K
  • EBIT $ -141 M
  • EBITDA $ -143 M
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 21.39

Options Overview Details

View History
  • Implied Volatility 196.31% (-5.80%)
  • Historical Volatility 85.81%
  • IV Percentile 58%
  • IV Rank 28.19%
  • IV High 445.66% on 05/23/25
  • IV Low 98.41% on 02/12/26
  • Expected Move (DTE 17) 7.17 (37.42%)
  • Put/Call Vol Ratio 0.74
  • Today's Volume 26,207
  • Volume Avg (30-Day) 6,125
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 109,170
  • Open Int (30-Day) 84,436
  • Expected Range 11.98 to 26.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 6
  • High Estimate $-0.09
  • Low Estimate $-0.59
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) -72.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.00 +36.79%
on 04/13/26
24.28 -21.13%
on 04/23/26
+4.18 (+27.92%)
since 03/27/26
3-Month
9.89 +93.73%
on 01/28/26
24.28 -21.13%
on 04/23/26
+8.65 (+82.38%)
since 01/27/26
52-Week
1.06 +1,706.60%
on 05/27/25
24.28 -21.13%
on 04/23/26
+17.76 (+1,277.70%)
since 04/25/25

Most Recent Stories

More News
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L...

ERAS : 19.15 (-10.89%)
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 19.15 (-10.89%)
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics ...

ERAS : 19.15 (-10.89%)
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting...

ERAS : 19.15 (-10.89%)
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO,...

ERAS : 19.15 (-10.89%)
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial...

ERAS : 19.15 (-10.89%)
Erasca to Present at Upcoming Conferences in February

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 19.15 (-10.89%)
Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock?

Erasca (ERAS) has surged 460% over the past year, driven by strong technical momentum. ERAS hit a new 3-year high of $10.92 on Monday. Despite bullish technicals, ERAS has no revenue, is burning cash,...

ERAS : 19.15 (-10.89%)
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 19.15 (-10.89%)
Erasca Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 19.15 (-10.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 23.54
2nd Resistance Point 22.60
1st Resistance Point 20.88
Last Price 19.15
1st Support Level 18.21
2nd Support Level 17.27
3rd Support Level 15.55

See More

52-Week High 24.28
Last Price 19.15
Fibonacci 61.8% 15.41
Fibonacci 50% 12.67
Fibonacci 38.2% 9.93
52-Week Low 1.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.